A phase 2 study of tislelizumab monotherapy in patients with previously treated, locally advanced unresectable ormetastatic microsatellite instability-high/mismatch repair deficient solid tumors.

doi:10.1200/JCO.2021.39.15_suppl.2569

	A phase 2 study of tislelizumab monotherapy in patients with previously treated, locally advanced unresectable ormetastatic microsatellite instability-high/mismatch repair deficient solid tumors.
	Li, Jian ; Xu, Ye ; Zang, Aimin ; Gao, Yunong ; Gao, Quanli ; Zhang, Yanqiao ; Wang, Dong ; Xu, Jianming ; Yuan, Ying ; Jiang, Haiping
刊名	JOURNAL OF CLINICAL ONCOLOGY
	2021-05-20
卷号	39
ISSN号	0732-183X
DOI	10.1200/JCO.2021.39.15_suppl.2569
资助项目	BeiGene, Ltd. - BeiGene, Ltd
WOS研究方向	Oncology
语种	英语
出版者	LIPPINCOTT WILLIAMS & WILKINS
WOS记录号	WOS:000708120601090
资助机构	BeiGene, Ltd. - BeiGene, Ltd
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/126526]
专题	中国科学院合肥物质科学研究院
作者单位	1.Henan Canc Hosp, Zhengzhou, Henan, Peoples R China 2.Harbin Med Univ, Canc Hosp, Dept Gastrointestinal Med Oncol, Harbin, Peoples R China 3.Chongqing Univ, Canc Hosp, Chongqing, Peoples R China 4.Chinese Peoples Liberat Army Gen Hosp, Med Ctr 5, Beijing, Peoples R China 5.Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China 6.Hubei Canc Hosp, Wuhan, Hubei, Peoples R China 7.Hebei Univ, Affiliated Hosp, Baoding, Hebei, Peoples R China 8.BeiGene Shanghai Co Ltd, Shanghai, Peoples R China 9.Hunan Canc Hosp, Changsha, Hunan, Peoples R China 10.Zhejiang Univ, Sch Med, Affiliated Hosp 2, Hangzhou, Zhejiang, Peoples R China
推荐引用方式 GB/T 7714	Li, Jian,Xu, Ye,Zang, Aimin,et al. A phase 2 study of tislelizumab monotherapy in patients with previously treated, locally advanced unresectable ormetastatic microsatellite instability-high/mismatch repair deficient solid tumors.[J]. JOURNAL OF CLINICAL ONCOLOGY,2021,39.
APA	Li, Jian.,Xu, Ye.,Zang, Aimin.,Gao, Yunong.,Gao, Quanli.,...&Shen, Lin.(2021).A phase 2 study of tislelizumab monotherapy in patients with previously treated, locally advanced unresectable ormetastatic microsatellite instability-high/mismatch repair deficient solid tumors..JOURNAL OF CLINICAL ONCOLOGY,39.
MLA	Li, Jian,et al."A phase 2 study of tislelizumab monotherapy in patients with previously treated, locally advanced unresectable ormetastatic microsatellite instability-high/mismatch repair deficient solid tumors.".JOURNAL OF CLINICAL ONCOLOGY 39(2021).